Non-steroidal Anti-inflammatory Drugs, Acetaminophen, and Risk of Skin Cancer in the Nurses' Health Study

Overview

Journal Cancer Causes Control

Specialties Oncology
Public Health

Date 2012 Jul 6

PMID 22763500

Citations 20

Authors

J M Jeter

J Han

M E Martinez

D S Alberts

A A Qureshi

D Feskanich

Affiliations

Soon will be listed here.

Abstract

Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with lower risk of certain cancers, but data on the effect on skin cancer risk have been limited and contradictory. We prospectively examined whether use of NSAIDS or acetaminophen was associated with a lower risk of skin cancer in women.

Methods: The 92,125 Caucasian women in the Nurses' Health Study provided information on aspirin use in 1980. Other NSAIDs and acetaminophen were added in 1990. Medication use, frequency, and quantity were reassessed on biennial questionnaires. Through 2008, we confirmed 658 melanoma cases, 1,337 squamous cell carcinoma (SCC) cases, and had 15,079 self-reports of basal cell carcinoma (BCC). We used COX proportional hazards models to compute relative risks (RR) adjusted for known skin cancer risk factors.

Results: Neither aspirin nor non-aspirin NSAID use was associated with a lower risk of melanoma, SCC, or BCC, even for women with high quantity, frequency, or duration of use. Instead, we observed an increased risk of melanoma among current aspirin users (RR = 1.32, 95 % CI 1.03-1.70), though an increase of similar magnitude among past users and lack of a dose-response effect did not support a pharmacologic mechanism. We observed a mild reduction in SCC risk in current acetaminophen users (RR = 0.88, 95 % CI 0.75-1.02), with a linear decrease in risk with greater frequency of use (p = 0.04).

Conclusions: Aspirin and other NSAIDs were not associated with a lower risk of melanoma, SCC, or BCC in women. Our large, prospective study does not support a chemoprotective effect of NSAIDs against skin cancers.

Citing Articles

Aspirin as a chemopreventive agent for cutaneous melanoma: a literature review.

Pulumati A, Algarin Y, Jaalouk D, Kim S, Latta S, Nouri K Arch Dermatol Res. 2024; 316(7):367.

PMID: 38850411 DOI: 10.1007/s00403-024-03056-3.

Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives.

Russomanno K, Azim S, Patel V Clin Cosmet Investig Dermatol. 2023; 16:1025-1045.

PMID: 37095898 PMC: 10122480. DOI: 10.2147/CCID.S362171.

The Association Between Aspirin and Basal Cell Carcinoma: A Clinical and Financial Analysis.

Frankel L, Ardeljan A, Takabe K, Rashid O World J Oncol. 2023; 13(6):343-349.

PMID: 36660204 PMC: 9822678. DOI: 10.14740/wjon1533.

Use of Nonsteroidal Anti-Inflammatory Drugs and Incidence of Melanoma in the United States Radiologic Technologists Study.

Mai J, Kitahara C, Sargen M, Little M, Alexander B, Linet M Cancer Prev Res (Phila). 2022; 15(11):727-732.

PMID: 35902885 PMC: 9633366. DOI: 10.1158/1940-6207.CAPR-22-0229.

Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial.

Yan M, Orchard S, Adler N, Wolfe R, McLean C, Rodriguez L Cancer Epidemiol. 2022; 79:102173.

PMID: 35567859 PMC: 10026004. DOI: 10.1016/j.canep.2022.102173.

References

Gruber S, Roush G, Barnhill R . Sensitivity and specificity of self-examination for cutaneous malignant melanoma risk factors. Am J Prev Med. 1993; 9(1):50-4. View

Feskanich D, Willett W, Hunter D, Colditz G . Dietary intakes of vitamins A, C, and E and risk of melanoma in two cohorts of women. Br J Cancer. 2003; 88(9):1381-7. PMC: 2741035. DOI: 10.1038/sj.bjc.6600882. View

WOLF A, Hunter D, Colditz G, Manson J, Stampfer M, Corsano K . Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol. 1994; 23(5):991-9. DOI: 10.1093/ije/23.5.991. View

Fairfield K, Hunter D, Fuchs C, Colditz G, Hankinson S . Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control. 2002; 13(6):535-42. DOI: 10.1023/a:1016380917625. View

Subongkot S, Frame D, Leslie W, Drajer D . Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy. 2003; 23(1):9-28. DOI: 10.1592/phco.23.1.9.31916. View

Zhang J, Bowden G . UVB irradiation regulates Cox-2 mRNA stability through AMPK and HuR in human keratinocytes. Mol Carcinog. 2008; 47(12):974-83. DOI: 10.1002/mc.20450. View

Vad N, Kudugunti S, Graber D, Bailey N, Srivenugopal K, Moridani M . Efficacy of acetaminophen in skin B16-F0 melanoma tumor-bearing C57BL/6 mice. Int J Oncol. 2009; 35(1):193-204. DOI: 10.3892/ijo_00000329. View

Scherer D, Kumar R . Genetics of pigmentation in skin cancer--a review. Mutat Res. 2010; 705(2):141-153. DOI: 10.1016/j.mrrev.2010.06.002. View

Chan A, Giovannucci E, Meyerhardt J, Schernhammer E, Curhan G, Fuchs C . Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005; 294(8):914-23. PMC: 1550973. DOI: 10.1001/jama.294.8.914. View

10.

Vogel U, Christensen J, Wallin H, Friis S, Nexo B, Tjonneland A . Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res. 2007; 617(1-2):138-46. DOI: 10.1016/j.mrfmmm.2007.01.005. View

11.

Schernhammer E, Kang J, Chan A, Michaud D, Skinner H, Giovannucci E . A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst. 2004; 96(1):22-8. DOI: 10.1093/jnci/djh001. View

12.

Curiel-Lewandrowski C, Nijsten T, Gomez M, Hollestein L, Atkins M, Stern R . Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol. 2011; 131(7):1460-8. DOI: 10.1038/jid.2011.58. View

13.

Chan A, Manson J, Feskanich D, Stampfer M, Colditz G, Fuchs C . Long-term aspirin use and mortality in women. Arch Intern Med. 2007; 167(6):562-72. DOI: 10.1001/archinte.167.6.562. View

14.

Demierre M, Nathanson L . Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol. 2002; 21(1):158-65. DOI: 10.1200/JCO.2003.07.173. View

15.

Harris R, Namboodiri K . Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep. 2001; 8(3):655-7. DOI: 10.3892/or.8.3.655. View

16.

Joosse A, Koomen E, Casparie M, Herings R, Guchelaar H, Nijsten T . Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol. 2009; 129(11):2620-7. DOI: 10.1038/jid.2009.201. View

17.

Grau M, Baron J, Langholz B, Karagas M, Greenberg E, Stukel T . Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer. 2006; 119(3):682-6. DOI: 10.1002/ijc.21878. View

18.

Ramirez C, Ma F, Federman D, Kirsner R . Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg. 2005; 31(7 Pt 1):748-52. DOI: 10.1097/00042728-200507000-00003. View

19.

Holmes M, Chen W, Li L, Hertzmark E, Spiegelman D, Hankinson S . Aspirin intake and survival after breast cancer. J Clin Oncol. 2010; 28(9):1467-72. PMC: 2849768. DOI: 10.1200/JCO.2009.22.7918. View

20.

Vad N, Yount G, Moore D, Weidanz J, Moridani M . Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines. J Pharm Sci. 2008; 98(4):1409-25. PMC: 2650003. DOI: 10.1002/jps.21505. View